Article
Fluctuation of Acquired Resistance Mutations and Re-Challenge with EGFR TKI in Metastatic NSCLC: A Case Report.
Current oncology (Toronto, Ont.) - 28 Sept 2023
Falk Markus, Schatz Stefanie, Reich Fabian P M, Schmidt Stefanie, Galster Marco, Tiemann Markus, Ficker Joachim H, Brueckl Wolfgang M
Abstract excerpt
Osimertinib has become the preferred first-line therapy for epidermal growth factor receptor (EGFR) mutation-positive metastatic non-small cell lung cancer (NSCLC) in recent years. Originally, it was approved for second-line treatment after epidermal growth factor receptor EGFR tyrosine kinase inhibitors (TKIs) of the first and second generations had failed and EGFR T790M had emerged as a mode of resistance....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.